Maishi N, Sakurai Y, Hatakeyama H, Umeyama Y, Nakamura T, Endo R, Alam MT, Li C, Annan DA, Kikuchi H, Morimoto H, Morimoto M, Akiyama K, Ohga N, Hida Y, Harashima H, Hida K.. Novel antiangiogenic therapy targeting biglycan in tumor endothelial cells using liposomal-siRNA delivery system. Cancer Sci, 345, 200-213 (2022) (IF 6.716)
Nakamura T, Kawakami K, Nomura M, Sato Y, Hyodo M, Hatakeyama H, Hayakawa Y, Harashima H. Combined nano cancer immunotherapy based on immune status in a tumor microenvironment. J Control Release, 345, 200-213 (2022) (IF 11.467)
Tanaka A, Honda T, Yasue M, Yamazaki R, Hatakeyama H, Hisaka A, Mashimo M, Kohama T, Nakamura H, Murayama T. Effects of ceramide kinase knockout on lipopolysaccharide-treated sepsis-model mice: Changes in serum cytokine/chemokine levels and increased lethality. J Pharmacol Sci, 150, 1-8 (2022) (IF 3.337)
Mayu Yamamoto, Taiki Kurino, Reiko Matsuda, Haleigh Sakura Jones, Yoshito Nakamura, Taisei Kanamori, Atushi B. Tsuji, Aya Sugyo, Ryota Tsuda, Yui Matsumoto, Yu Sakurai, Hiroyuki Suzuki, Makoto Sano, Kensuke Osada, Tomoya Uehara, Yukimoto Ishii, Hidetaka Akita, Yasushi Arano, Akihiro Hisaka, Hiroto Hatakeyama. Delivery of aPD-L1 antibody to i.p. tumors via direct penetration by i.p. route: Beyond EPR effect. J Control Release, 352, 328-337 (2022) (IF 11.467) https://doi.org/10.1016/j.jconrel.2022.10.032